Results 81 to 90 of about 138,421 (254)

Interleukin‐5, Eosinophils, and Interleukin‐5 Pathway Inhibitors in Eosinophilic Granulomatosis With Polyangiitis

Arthritis &Rheumatology, EarlyView.
Interlukin‐5 (IL‐5) plays a crucial role in the pathogenesis of eosinophilic granulomatosis with polyangiitis (EGPA) by promoting eosinophil differentiation, activation, and survival. We present here a typical case of EGPA in which treatment with IL‐5 pathway inhibitors is prescribed, showing to be beneficial for the patient.
Alvise Berti, Christian Pagnoux
wiley   +1 more source

Oxaliplatin-induced type II hypersensitivity in colorectal cancer: a cohort study on clinical presentation, diagnosis, and management

Frontiers in Pharmacology
BackgroundOxaliplatin (OXL) is a key treatment for colorectal cancer but can potentially induce type II hypersensitivity reactions (II-HSRs), leading to immune-mediated cytopenias.
Paula Vázquez-Revuelta, Paula Vázquez-Revuelta, Paula Vázquez-Revuelta, Paula Vázquez-Revuelta, Ricardo Madrigal-Burgaleta, Ricardo Madrigal-Burgaleta, J. Carlos Ruffinelli, Enric Casanovas, Ana Coloma, Ana Coloma, Ramon Lleonart, Ramon Lleonart   +11 more
doaj   +1 more source

Immunologic Profiling Suggests an Association Between Treg Cell Dysfunction and Pain in Knee Osteoarthritis

Arthritis &Rheumatology, EarlyView.
Objective Pain is the hallmark symptom of osteoarthritis (OA), and its biologic drivers remain poorly understood. Although the role of innate immunity in OA has been extensively studied, the involvement of adaptive immunity, in particular Treg cells, is not well understood.
Marie Binvignat, Johanna Dubois, Maria Marco Salvador, Paul Stys, Fabien Pitoiset, Alexandra Roux, Michèle Sastre, Signe Hassler, Roberta Lorenzon, Claire Ribet, Vanessa Mhanna, Hélène Vantomme, Leslie Adda, Pierre Barennes, Nicolas Coatnoan, Kenz Le Gouge, Caroline Aheng, Alice Courties, Lise Minssen, Atul J. Butte, Adrien Six, Michelle Rosenzwajg, Nicolas Tchitchek, Francis Berenbaum, David Klatzmann, Encarnita Mariotti‐Ferrandiz, Jérémie Sellam   +26 more
wiley   +1 more source

Plasma Proteomics Identifies Thousand‐and‐One–Amino Acid Kinase 3 as a Potential Biomarker of Rheumatoid Arthritis Activity and a Novel Therapeutic Target

Arthritis &Rheumatology, EarlyView.
Objective Bone destruction associated with active rheumatoid arthritis (RA) remains a major therapeutic challenge, with a lack of reliable molecular markers reflecting bone injury. This study aims to identify novel biomarkers linked to bone destruction in active RA through proteomic analysis, providing new strategies for precise monitoring and targeted
Pengfei Xin, Wenzhen Li, Xinyu A, Jun Shen, Xiaohui Meng, Yanqin Bian, Haihui Han, Zheng Xiang, Lei Ran, Songtao Sun, Jun Xie, Tao Yue, Qi Zhu, Xiaoming Zhang, Lu Xie, Lianbo Xiao   +15 more
wiley   +1 more source

Visual Hypersensitivity as a Transdiagnostic Marker of Surgical Pain Response in Arthritis and Chronic Pain Syndromes

Arthritis &Rheumatology, EarlyView.
Objective Nociplastic pain is pain primarily driven by the central nervous system and, unlike nociceptive pain conditions, is thought to be refractory to peripherally directed therapies. Nociplastic pain is also associated with hypersensitivity to painful and other sensory stimuli (such as visual stimuli). Nonpainful sensory measures have not been well
Noah Waller, Steven E. Harte, Richard E. Harris, Andrew Schrepf, Tristin Smith, Eric Ichesco, Chelsea Kaplan, Flavia Sunzini, Deeba Minhas, Wendy Marder, Sara R. Till, David A. Williams, Chad M. Brummett, Neil Basu, Sawsan As‐Sanie, Daniel J. Clauw   +15 more
wiley   +1 more source

Multi‐omic profiling reveals immune cell priming signature linked to lupus prognosis

Arthritis &Rheumatology, Accepted Article.
Objective Systemic lupus erythematosus (SLE) is a multi‐organ disease with widespread immune dysregulation and significant unmet clinical need. Blood‐based gene expression studies have advanced our understanding of SLE pathogenesis but may overlook critical tissue‐specific mechanisms that drive disease heterogeneity and progression.
Michael A. Smith, Dominic Sinibaldi, Saifur Rahman, Chia‐Chien Chiang, Anna M. Hansen, Jill Henault, Carlos P. Roca, Shu Wang, Kamelia Zerrouki, Rebecca Filippi, Christopher Groves, Zerai Manna, Jun Chu, Michael Davis, Sarthak Gupta, Christopher Morehouse, Melissa de los Reyes, Rachel Ettinger, Roland Kolbeck, Mariana J. Kaplan, Miguel A. Sanjuan, Richard M. Siegel, Sarfaraz A. Hasni, Kerry A. Casey   +23 more
wiley   +1 more source

Altered microbiome of serum exosomes in patients with acute and chronic cholecystitis

BMC Microbiology
Background This study aimed to investigate the differences in the microbiota composition of serum exosomes from patients with acute and chronic cholecystitis.
Qing Zhu, Min-Xian Li, Ming-Chin Yu, Qi-Wen Ma, Ming-Jie Huang, Chun-Wei Lu, Chun-Bing Chen, Wen-Hung Chung, Chih-Jung Chang   +8 more
doaj   +1 more source

Adverse immunostimulation in early phase clinical trials: Key findings and recommendations based on the investigator's clinical experience

British Journal of Clinical Pharmacology, EarlyView.
Problem setting The emergence of therapeutic proteins has coincided with an increase of acute adverse immunostimulation (AIS). AIS has occured in clinical trials despite compliance with regulatory guidelines on preclinical evaluation and its incidence is anticipated to increase even further.
Juliette A. van den Noort, Marella C. E. van Ruissen, Lisanne C. A. Smidt, Naomi B. Klarenbeek, Philip H. K. Kremer, Manon A. A. Jansen, Jacobus Burggraaf, Joop M. A. van Gerven, Matthijs Moerland   +8 more
wiley   +1 more source

AASLD practice guidance on drug, herbal, and dietary supplement–induced liver injury

, 2022
Hepatology, EarlyView.
Robert J. Fontana, Iris Liou, Adrian Reuben, Ayako Suzuki, M. Isabel Fiel, William Lee, Victor Navarro   +6 more
wiley   +1 more source

Age‐related differences in hydroxychloroquine‐associated adverse events: A pharmacovigilance study based on the FDA Adverse Event Reporting System

British Journal of Clinical Pharmacology, EarlyView.
Aims This real‐world pharmacovigilance study utilizes FDA Adverse Event Reporting System (FAERS) data (2004–2024) to characterize age‐related disparities in hydroxychloroquine (HCQ)‐associated adverse events (AEs), addressing gaps in age‐stratified risk assessment. Methods Disproportionality analysis (reporting odds ratios, RORs) and parametric Weibull
Guanghan Sun, Jingrong Yang, Lei Wan, Xia Xu, Jing Wang   +4 more
wiley   +1 more source